{
    "clinical_study": {
        "@rank": "18336", 
        "acronym": "POR", 
        "arm_group": [
            {
                "arm_group_label": "mild ovarian stimulation", 
                "arm_group_type": "Experimental", 
                "description": "Patients are stimulated with mild ovarian stimulation protocol,i.ed, from cycle day 3 to 7, letrozole 5mg per day are administrated and recombinant FSH 150 IU are given on day 4 and 6 . On cycle day 8, serum FSH LH, and estradiol levels are measured, and after then, the dose of recombinant FSH is adjusted according to the ovarian response and the maxim recombinant FSH dose is 150 IU/d. The GnRH-antagonist (Cetrotide) 0.25mg per day is administrated when the estradiol level reaches 200 pg/ml and the serum LH level rises above 2 times of basal LH level."
            }, 
            {
                "arm_group_label": "controlled ovarian stimulation", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients are stimulated using controlled ovarian stimulation protocol,i.e., from cycle day 18-22 (day 7 after ovulation) of previous cycle, all participants are given short-acting GnRH agonist (Triptorelin 0.05mg/d) for 14 days, then after checking serum FSH, LH and estradiol to make sure that complete downregulation is achieved, exogenous gonadotropin (recombinant FSH) 300 IU/d is given for 5 days, then the dose of recombinant FSH is adjusted according to ovarian response."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a prospective, randomized clinical trial to compare the efficiency and safety of\n      mild stimulation and controlled ovarian stimulation protocol on the treatment of POR. The\n      randomization is achieved on the basis of a computer-generated randomization list in a 1:1\n      ratio."
        }, 
        "brief_title": "Comparison of Ovarian Mild Stimulation and Controlled Ovarian Stimulation in Poor Ovarian Responders", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Infertility", 
        "condition_browse": {
            "mesh_term": "Infertility"
        }, 
        "detailed_description": {
            "textblock": "500 poor ovarian responders will be equally randomized to two different ovarian stimulation\n      protocol arms,i.e, mild ovarian stimulation(experimental arm) or controlled ovarian\n      stimulation(control arm). In experimental arm, patients will received letrozole 5mg per day\n      from cycle day 3 to 7 and recombinant follicle-stimulating hormone (FSH) 150 international\n      unit (IU) on day 4 and 6. The dose of recombinant FSH is adjusted according to the ovarian\n      response and the gonadotropin-releasing hormone(GnRH)antagonist(Cetrotide) 0.25mg per day is\n      administrated when the estradiol level reaches 200 pg/ml and the serum luteinizing hormone\n      \uff08LH\uff09level rises above 2 times of basal LH level. In control arm,patients will be stimulated\n      with short-acting GnRH agonist long protocol. After complete downregulation is achieved\n      through GnRH-agonist, recombinant FSH 300 IU/d is given for 5 days, then the dose of\n      recombinant FSH is adjusted according to ovarian response.\n\n      The clinical and ongoing pregnancy rate and other secondary outcome parameters are compared\n      between these two groups."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  a. Poor ovarian responders b. Normal BMI (18-25 Kg/m2) c. Regular menstruation (with\n             cycle 23-35 days)\n\n        Exclusion Criteria:\n\n          -  a. History of repeated IVF failure (previous IVF cycle \uff1e2) b. Serious adenomyosis c.\n             Polycystic ovary syndrome(PCOS) patients d. History of allergic to ovulation\n             induction medicines e. Abnormal uterine cavity, i.e, intrauterine adhesion f.\n             Attending other clinical trials in the same period. g. History of systemic disease\n             contradictory to COH or pregnancy."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01926210", 
            "org_study_id": "A-2013-01-05S"
        }, 
        "intervention": [
            {
                "arm_group_label": "mild ovarian stimulation", 
                "description": "letrozole is used from cycle day 3 to 7 and low dose recombinant FSH(no more than 150 IU/d) is used on cycle day 4,6 and 8 onwards. GnRH antagonist is only applied in case of premature LH rise might happen.", 
                "intervention_name": "mild stimulation protocol", 
                "intervention_type": "Other", 
                "other_name": [
                    "letrozole", 
                    "recombinant FSH", 
                    "GnRH antagonist"
                ]
            }, 
            {
                "arm_group_label": "controlled ovarian stimulation", 
                "description": "After fully downregulation by using short-acting GnRH agonist, 300 IU/d recombinant FSH is administrated for 5 days, then the dose is adjusted according to ovarian response.", 
                "intervention_name": "controlled ovarian stimulation", 
                "intervention_type": "Other", 
                "other_name": [
                    "GnRH agonist", 
                    "recombinant FSH"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Deslorelin", 
                "Letrozole"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Poor ovarian response", 
            "in vitro fertilization", 
            "mild ovarian stimulation", 
            "controlled ovarian stimulation"
        ], 
        "lastchanged_date": "August 20, 2013", 
        "location": {
            "contact": {
                "email": "dengyu1983@yahoo.com.cn", 
                "last_name": "Yu Deng, M.D."
            }, 
            "facility": {
                "address": {
                    "city": "Guangzhou", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "510010"
                }, 
                "name": "sixth affiliated hospital of Sun Yet-san University"
            }, 
            "investigator": {
                "last_name": "Rui Huang, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Comparison of Mild Stimulation and Controlled Ovarian Stimulation in Poor Ovarian Responders: a Prospective Randomized Study.", 
        "overall_contact": {
            "email": "yxing8358@gmail.com", 
            "last_name": "Xing Yang, M.D."
        }, 
        "overall_official": {
            "affiliation": "sixth affiliated hospital of Sun Yet-san University", 
            "last_name": "Rui Huang, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "clinical pregnancy rate", 
            "safety_issue": "No", 
            "time_frame": "7 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01926210"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sun Yat-sen University", 
            "investigator_full_name": "Huang Rui", 
            "investigator_title": "M.D.", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "live birth rate", 
                "safety_issue": "No", 
                "time_frame": "10 months"
            }, 
            {
                "measure": "Number of oocytes retrieved", 
                "safety_issue": "No", 
                "time_frame": "3 weeks"
            }, 
            {
                "measure": "Number of transferrable embryo", 
                "safety_issue": "No", 
                "time_frame": "3 weeks"
            }, 
            {
                "measure": "normal fertilization rate", 
                "safety_issue": "No", 
                "time_frame": "3 weeks"
            }, 
            {
                "measure": "implantation rate", 
                "safety_issue": "No", 
                "time_frame": "7 weeks"
            }, 
            {
                "measure": "ongoing pregnancy rate", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Total dose of recombinant FSH consumption", 
                "safety_issue": "No", 
                "time_frame": "3 weeks"
            }, 
            {
                "measure": "length of stimulation", 
                "safety_issue": "No", 
                "time_frame": "3 weeks"
            }, 
            {
                "measure": "serum estradiol level", 
                "safety_issue": "No", 
                "time_frame": "3 weeks"
            }, 
            {
                "measure": "serum LH level", 
                "safety_issue": "No", 
                "time_frame": "3 weeks"
            }, 
            {
                "measure": "serum progesterone level", 
                "safety_issue": "No", 
                "time_frame": "3 weeks"
            }, 
            {
                "measure": "serum FSH level", 
                "safety_issue": "No", 
                "time_frame": "3 weeks"
            }, 
            {
                "measure": "FSH level in follicular fluid", 
                "safety_issue": "No", 
                "time_frame": "3 weeks"
            }, 
            {
                "measure": "LH level in follicular fluid", 
                "safety_issue": "No", 
                "time_frame": "3 weeks"
            }, 
            {
                "measure": "Estradiol level in the follicular fluid", 
                "safety_issue": "No", 
                "time_frame": "3 weeks"
            }, 
            {
                "measure": "progesterone level in follicular fluid", 
                "safety_issue": "No", 
                "time_frame": "3 weeks"
            }, 
            {
                "measure": "testerone level in the follicular fluid", 
                "safety_issue": "No", 
                "time_frame": "3 weeks"
            }, 
            {
                "measure": "anti-m\u00fcllerian hormone (AMH)level in follicular fluid", 
                "safety_issue": "No", 
                "time_frame": "3 weeks"
            }, 
            {
                "measure": "Ovarian Hyperstimulation Syndrome (OHSS) rate", 
                "safety_issue": "Yes", 
                "time_frame": "7 weeks"
            }
        ], 
        "source": "Sun Yat-sen University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Huang Rui", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}